Syros Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Let me say again, thank you, everybody, for being here in person at the JMP Securities 2022 life sciences conference. Next company we have with us is Syros Pharmaceuticals. We have Nancy Simonian, company's CEO. Nancy, welcome.
Thank you.
So again, another busy year for you. So maybe I'd just offer it to you to give a quick high-level intro of Syros, your lead programs, and we'll jump in from there.
Yeah. It's an incredibly exciting time at the company. We have three programs in clinical development. Our most advanced, tamibarotene, is at a Phase 3 registration-enabling study in high-risk MDS. We expect data from that study end of 2023, early 2024. We also have tamibarotene being studied in AML, and we will have data later this year from a safety lead-in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
